Szilard Voros, MD, FACC, FSCCT, FAHA, Founder & CEO, Global Genomics Group (G3), explains his company’s goals to fill the two main gaps in treating cardiovascular disease:
1) Creating a simple blood test to diagnose cardiovascular disease
2) Creating better pharmacotherapy to prevent initial or secondary heart attacks
The Global Project, G3’s flagship project, has 3 pillars that are critical to understanding cardiovascular disease:
1) Imaging: Using the latest, high-end imaging technology to tell if a patient has heart disease
2) Panomics: Combining the entire range of molecular biology technologies like genomics, proteomics, metabolomics, transcriptomics, etc.
3) Systems Biology-Driven Bioinformatics: Looking at cardiovascular disease through new and unbiased tools
Resources & References:
– http://www.clinicaltrials.gov/ct2/show/NCT01738828?lead=Global+Genomics+Group&rank=1
